# Mocertatug Rezetecan, known as Mo-Rez, shrank or eliminated tumours in 62% of patients with ovarian cancer where chemotherapy.

*biotech · news · 2026-04-12 · The Guardian*

## Key points

- GSK's Mo-Rez shrank or eliminated tumors in 62% of ovarian and 67% of endometrial cancer patients.
- GSK acquired Mo-Rez from China's Hansoh Pharma in late 2023 and trialed it in 224 patients globally.
- Positive early and intermediate trial data allow GSK to proceed directly to late-stage global trials for Mo-Rez.
- Mo-Rez is projected to be a blockbuster drug, expected to exceed £2bn in annual peak sales.
- GSK's oncology sales rose 43% last year, with four approved cancer drugs and 13 in clinical development.

**Companies:** GSK, AstraZeneca
**Countries:** United Kingdom, China, Australia, Puerto Rico

[Read the full story on The Guardian](https://www.theguardian.com/business/2026/apr/12/gsk-promising-early-results-ovarian-womb-cancer-drug-trial)

---

Canonical: https://newsio.io/n/5868e4a4-0ed6-45d8-b479-ea96c6e930a1/mocertatug-rezetecan-known-as-mo-rez-shrank-or-eliminated-tumours-in-62-of-patie
Summarized by Newsio from The Guardian. https://newsio.io/how-it-works